BSG and cancer: Notably, although CD147 knockdown per se delayed tumor progression to a lesser extent, the combination of CD147 knockdown and paclitaxel treatment significantly shrunk the tumors (Fig. 2G and Supplementary Fig. 1F–H), suggesting that CD147 knockdown sensitizes cancer cells to paclitaxel.